SCHEMBL5267233

SCHEMBL5267233

CC(=O)c1cnn(C(c2ccccc2)(c2ccccc2)c2ccccc2)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
HTT P42858 1/20 0.39
KIF11 P52732 4/20 0.39
ALKBH2 Q6NS38 2/20 0.39
HPGDS O60760 1/20 0.39
KMT2A Q03164 2/20 0.37
MAPK1 P28482 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 2/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
EGLN1 Q9GZT9 2/20 0.35
ITK Q08881 1/20 0.34
TAAR1 Q96RJ0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5267243 0.87 ALKBH2 (0.53) MAPTSMN1; SMN2NPC1RAB9AHTT
SCHEMBL27985786 0.83 BAZ2B (0.42) MAPTSMN1; SMN2NPC1RAB9AHTT
SCHEMBL5269393 0.83 TSHR (0.47) MAPTNPC1RAB9AKMT2AMAPK1
SCHEMBL5267207 0.79 MLYCD (0.44) MAPTSMN1; SMN2NPC1RAB9AHTT
SCHEMBL27986132 0.77 ELANE (0.41) MAPTNPC1HTTKMT2AMAPK1
SCHEMBL27745237 0.76 TDP1 (0.53) MAPTSMN1; SMN2NPC1RAB9AHTT
SCHEMBL15287294 0.75 MAPT (0.48) MAPTSMN1; SMN2NPC1RAB9AHTT
SCHEMBL9375079 0.75 MAPT (0.50) MAPTSMN1; SMN2NPC1RAB9AHTT
SCHEMBL7254281 0.74 GAA (0.48) ALKBH2HPGDSALDH1A1ITK
SCHEMBL8313319 0.74 KCNN4 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025106014-A1 COMPOUNDS AND METHODS FOR PKMYT1 INHIBITION ENGINE BIOSCIENCES PTE. LTD. (SG) 2025-05-22 WO disclosed
CN-114846004-B Antimalarial drugs 德克萨斯大学系统董事会 2024-10-11 CN disclosed
US-11903936-B2 Anti-malarial agents THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-02-20 US disclosed
US-20230056202-A1 ANTI-MALARIAL AGENTS MMV MEDICINES FOR MALARIA VENTURE (CH) 2023-02-23 US disclosed
CN-114846004-A Novel antimalarial drug 德克萨斯大学系统董事会 2022-08-02 CN disclosed
US-20070254881-A1 Pyrazole Derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-11-01 US disclosed
EP-1785418-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-05-16 EP disclosed
EP-1633306-A4 USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS MERCK & CO INC (US) 2007-05-16 EP disclosed
EP-1633306-A2 USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS Merck & Co., Inc. (US) 2006-03-15 EP disclosed
WO-2004105698-A2 USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS MERCK & CO., INC. (US) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254881-A1 Pyrazole Derivative PTGER1, PTGS1, PTGER2 MAPT 4006/4885SMN1; SMN2 3490/4885NPC1 4323/4885
US-11903936-B2 Anti-malarial agents PYCR1, DHFR, QDPR MAPT 2471/4885SMN1; SMN2 3667/4885NPC1 2479/4885
US-20230056202-A1 ANTI-MALARIAL AGENTS PYCR1, DHFR, QDPR MAPT 2471/4885SMN1; SMN2 3667/4885NPC1 2479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.